Table 5.
Correlation between cancer recurrence and wild-type or mutated PTCH1 in patients with breast cancer who underwent radical resection and standard adjuvant therapy.
| Wild-type PTCH1 | Mutated PTCH1 | p-value | |
|---|---|---|---|
| Patients, n (%) | 25 (57%) | 19 (43%) | |
| Recurrence | 9 (41%) | 13 (59%) | 0.067 |
| Lung metastasis | 5 (31%) | 11 (69%) | 0.013* |
| Liver metastasis | 2 (20%) | 8 (80%) | 0.011* |
| Bone metastasis | 6 (40%) | 9 (60%) | 0.123 |
| Brain metastasis | 3 (50%) | 3 (50%) | >0.999 |
| Regional lymph node recurrence | 2 (40%) | 3 (60%) | 0.638 |
| Distant lymph node metastasis | 4 (31%) | 9 (69%) | 0.044* |
| Local recurrence | 0 | 2 (100%) | 0.181 |
| Skin metastasis | 1 (50%) | 1 (50%) | >0.999 |
| Adrenal gland metastasis | 1 (50%) | 1 (50%) | >0.999 |
| Splenic metastasis | 1 (33%) | 2 (67%) | 0.570 |
*p-value less than 0.05.